Pluristem Therapeutics Inc. Stock Nasdaq
Equities
US72940R1023
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 234K | Sales 2023 | 287K | Capitalization | 32.98M |
---|---|---|---|---|---|
Net income 2022 | -41M | Net income 2023 | -28M | EV / Sales 2022 | 58 x |
Net cash position 2022 | 26.21M | Net cash position 2023 | 10.27M | EV / Sales 2023 | 79.1 x |
P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-1.04
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.38% |
Managers | Title | Age | Since |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 06-10-31 |
Director of Finance/CFO | 40 | 13-04-30 | |
Zami Aberman
CHM | Chairman | 70 | 05-09-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 21-07-14 | |
Lorne Abony
BRD | Director/Board Member | 55 | 23-07-10 |
Zami Aberman
CHM | Chairman | 70 | 05-09-25 |
1st Jan change | Capi. | |
---|---|---|
+1.70% | 42.59B | |
+7.86% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+9.36% | 24.81B | |
-24.48% | 18.17B | |
+27.99% | 12.05B | |
-3.31% | 11.7B | |
+6.89% | 11.1B |